Clinical trial
FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small…
NCT00086333 · Seagen Inc., Industry · Completed
Key facts
| NCT number | NCT00086333 |
|---|---|
| Title | FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma |
| Official title | A Phase II Study Using FDG-PET to Investigate the Dosing Schedule and Response of Combination SGN-15 (cBR96-Doxorubicin Immunoconjugate) and Docetaxel in Patients With Stage IV or Stage IIIB Non-Small Cell Lung Carcinoma Ineligible for Combined Modality Treatment With Curative Intent |
| Lead sponsor | Seagen Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | SGN-15, Docetaxel |
| Enrollment | 30 |
| Start date | Jul 1, 2004 |
| Completion | Dec 1, 2005 |
| First posted | Jul 2, 2004 |
| Last update posted | Oct 24, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: